<table border="0" cellpadding="0" cellspacing="0" width="637" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table II: Cardiac Events and All-Cause Mortality (events per 1000 patients) Occurring During the 3.5 Year Open-Label Follow-up to the Helsinki Heart Study<sup>1</sup>
</caption>
<thead>
<tr>
<th stylecode="Lrule Rrule Toprule">Group:</th>
<th align="center" stylecode="Lrule Rrule Toprule">PDrop<br/>N=215</th>
<th align="center" stylecode="Lrule Rrule Toprule">PN<br/>N=494</th>
<th align="center" stylecode="Lrule Rrule Toprule">PG<br/>N=1283</th>
<th align="center" stylecode="Lrule Rrule Toprule">GDrop<br/>N=221</th>
<th align="center" stylecode="Lrule Rrule Toprule">GN<br/>N=574</th>
<th align="center" stylecode="Lrule Rrule Toprule">GG<br/>N=1207</th>
</tr>
</thead>
<tfoot>
<tr>
<td colspan="7">
<sup>1 </sup>The six open-label groups are designated first by the original randomization (P = placebo, G = gemfibrozil) and then by the drug taken in the follow-up period (N = Attend clinic but took no drug, G = gemfibrozil, Drop = No attendance at clinic during open-label). <br/>
</td>
</tr>
</tfoot>
<tbody>
<tr>
<td stylecode="Lrule Rrule" valign="top">   Cardiac Events<br/>   All-Cause Mortality<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">38.8<br/>41.9<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">22.9<br/>22.3<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">22.5<br/>15.6<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">37.2<br/>72.3<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">28.3<br/>19.2<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">25.4<br/>24.9<br/>
</td>
</tr>
</tbody>
</table>